SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Aminophylline Injection, USP (Hospira Inc.)
Trade Name: Aminophylline Injection, USP
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of asthma

Details of the Supplier of the Safety Data Sheet
Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

PZ03246
### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminophylline Dihydrate</td>
<td>5897-66-5</td>
<td>Not Listed</td>
<td>Acute Tox 3 (H301)</td>
<td>2.5</td>
</tr>
<tr>
<td>1,2-DIAMINOETHANE</td>
<td>107-15-3</td>
<td>203-468-6</td>
<td>Acute Tox. 4 (H302)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Skin Corr. 1B (H314)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Skin Sens. 1 (H317)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Resp. Sens. 1 (H334)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Flam. Liq. 3 (H226)</td>
<td></td>
</tr>
<tr>
<td>Water for injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

**Additional Information:**
- * Proprietary
- ** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

- **Eye Contact:** Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
- **Skin Contact:** Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.
- **Ingestion:** Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
- **Inhalation:** Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

**Most Important Symptoms and Effects, Both Acute and Delayed**

- **Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- **Medical Conditions Aggravated by Exposure:** None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

- **Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

- **Extinguishing Media:** As for primary cause of fire.
- **Special Hazards Arising from the Substance or Mixture**
  - **Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.
  - **Fire / Explosion Hazards:** Not applicable
Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. Use with adequate ventilation. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Incompatible Materials: None
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Aminophylline Dihydrate
Pfizer OEL TWA-8 Hr: 800µg/m³

1,2-DIAMINOETHANE
ACGIH Threshold Limit Value (TWA) 10 ppm
ACGIH - Skin Absorption Designation Skin - potential significant contribution to overall exposure by the cutaneous route
Australia TWA 10 ppm
25 mg/m³
Austria OEL - MAKs 10 ppm
25 mg/m³
Belgium OEL - TWA 10 ppm
25 mg/m³
Bulgaria OEL - TWA 25 mg/m³
Czech Republic OEL - TWA 25 mg/m³
Denmark OEL - TWA 10 ppm
25 mg/m³
Estonia OEL - TWA 10 ppm
25 mg/m³
Exposure Controls / Personal Protection

**Exposure Controls**

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment**

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:**

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:**

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:**

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

**Respiratory protection:**

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution
Odor: Not applicable
Molecular Formula: Mixture
Solvent Solubility: No data available
Water Solubility: Soluble
pH: 8.8 (8.6-9)
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available
Partition Coefficient: (Method, pH, Endpoint, Value)
Water for injection
No data available
Theophylline
No data available
1,2-DIAMINOETHANE
No data available
Aminophylline Dihydrate
No data available
Aminophylline
No data available
Decomposition Temperature (°C): No data available
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
Flammability:
  Autoignition Temperature (Solid) (°C): No data available
  Flammability (Solids): No data available
  Flash Point (Liquid) (°C): No data available
  Upper Explosive Limits (Liquid) (% by Vol.): No data available
  Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: None
  Conditions to Avoid: Not determined
  Incompatible Materials: None
  Hazardous Decomposition Products: Nitrogen oxides (nox), Oxides of carbon

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: There are no data for this formulation. The information in this section includes the potential hazards of the individual ingredients and/or of a chemically-related material.
Short Term: May cause eye and skin irritation.
11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include nausea, vomiting, headache, insomnia, diarrhea, irritability, restlessness, tremors, irregular heartbeat (cardiac arrhythmia), seizure.

Acute Toxicity: (Species, Route, End Point, Dose)

**Theophylline**
- Rat  Oral  LD 50  225 mg/kg
- Rat Mouse Sub-tenon injection (eye)  LD50  150mg/kg
- Mouse  Oral  LD50  235mg/kg

**Aminophylline Dihydrate**
- Mouse  Oral  LD50  250 mg/kg
- Mouse  IV  LD50  150mg/kg

**Aminophylline**
- Rat  Oral  LD50  243 mg/kg
- Mouse  Oral  LD50  150mg/kg
- Rat  IV  LD50  104mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Theophylline**
- 2 Week(s)  Rat  Oral  600 mg/kg  LOAEL  Lungs
- 13 Week(s)  Rat  Oral  5175 mg/kg  LOAEL  Liver, Kidney, Blood
- 19 Week(s)  Rat  Oral  39,900 mg/kg  LOAEL

**Reproductive & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

**Theophylline**
- Reproductive & Fertility-Males  Rat  Oral  10050 mg/kg  LOEL  Paternal toxicity
- Reproductive & Fertility - Females  Rat  Oral  1500 mg/kg  LOEL  Teratogenic
- Reproductive & Fertility-Females  Rat  Subcutaneous  1700 mg/kg  LOEL  Teratogenic
- Reproductive & Fertility-Females  Mouse  Oral  3 g/kg  LOEL  Teratogenic

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Theophylline**
- Bacterial Mutagenicity (Ames)  Bacteria  Positive

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Theophylline**
- 104 Week(s)  Rat  Oral  75 mg/kg/day  NOAEL  Not carcinogenic
- 104 Week(s)  Mouse  Oral  75 mg/kg/day  NOAEL  Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Theophylline IARC: Group 3 (Not Classifiable)
11. TOXICOLOGICAL INFORMATION

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Water for injection
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present

PZ03246
SAFETY DATA SHEET

Material Name: Aminophylline Injection, USP (Hospira Inc.)
Revision date: 03-Jan-2017

15. REGULATORY INFORMATION

| REACH - Annex IV - Exemptions from the | Present |
| obligations of Register:              |         |
| EU EINECS/ELINCS List                 | 231-791-2 |

Aminophylline Dihydrate

| CERCLA/SARA 313 Emission reporting  | Not Listed |
| California Proposition 65            | Not Listed |
| EU EINECS/ELINCS List                | Not Listed |

1,2-DIAMINOETHANE

| CERCLA/SARA 313 Emission reporting  | Not Listed |
| CERCLA/SARA Hazardous Substances    | 5000 lb    |
| and their Reportable Quantities:    | 2270 kg    |
| CERCLA/SARA - Section 302 Extremely Hazardous | 10000 lb |
| TPQs                                |           |
| CERCLA/SARA - Section 302 Extremely Hazardous | 5000 lb |
| Substances EPCRA RQs                |           |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS):                   | Present   |
| EU EINECS/ELINCS List               | 203-468-6 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Flammable liquids-Cat.3; H226 - Flammable liquid and vapor
Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Sensitization, respiratory-Cat.1; H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Revision date: 03-Jan-2017
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet